Stoke Therapeutics Presents Data Supporting the Disease-Modifying Potential of STK-002 in Autosomal Dominant Optic Atrophy (ADOA) at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting
Stoke Therapeutics presented natural history and preclinical data at AAO 2026 supporting the disease-modifying potential of STK-002, an antisense oligonucleotide targeting OPA1 deficiency in Autosomal Dominant Optic Atrophy. Dosing is complete in the first two cohorts of the Phase 1 OSPREY study, with the third cohort expected to complete by year-end 2026 and initial safety and efficacy data anticipated in H1 2027.
Key figures
- Drug Name
- STK-002
- Phase Of Trial
- Phase 1
- Data timing
- initial safety and efficacy data anticipated in H1 2027
- Falcon enrollment
- 47
- Osprey sites active
- 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.